<DOC>
	<DOCNO>NCT01310166</DOCNO>
	<brief_summary>The purpose study investigate change immunological biomarkers treatment fingolimod patient relapsing-remitting multiple sclerosis detect .</brief_summary>
	<brief_title>Biomarker Study After Initiation Treatment With Fingolimod ( FTY720 ) Patients With Relapsing-remitting Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Subjects relapse form MS define 2005 revise McDonald criterion Patients Expanded Disability Status Scale ( EDSS ) score 06.5 Patients manifestation MS relapse remit MS Patients history chronic disease immune system MS know immunodeficiency syndrome History presence malignancy last 5 year Diabetic patient moderate severe nonproliferative diabetic retinopathy proliferative diabetic retinopathy uncontrolled diabetic patient Diagnosis macular edema Screening Phase Patients active systemic bacterial , viral fungal infection Negative varicellazoster virus IgG antibody Screening Patients treated cladribine , cyclophosphamide mitoxantrone time History cardiovascular disorder Women childbaring potential inadequate contraception Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Multiple sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>relapsing-remitting</keyword>
	<keyword>fingolimod</keyword>
	<keyword>biomarkers</keyword>
</DOC>